You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Efficacy of Alteplase in a Mouse Model of Acute Ischemic Stroke
|
|---|---|
| Published in |
Stroke, March 2016
|
| DOI | 10.1161/strokeaha.116.012238 |
| Pubmed ID | |
| Authors |
Cyrille Orset, Benoit Haelewyn, Stuart M Allan, Saema Ansar, Francesco Campos, Tae Hee Cho, Anne Durand, Mohamad El Amki, Marc Fatar, Isaac Garcia-Yébenes, Maxime Gauberti, Saskia Grudzenski, Ignacio Lizasoain, Eng Lo, Richard Macrez, Isabelle Margaill, Samaneh Maysami, Stephen Meairs, Norbert Nighoghossian, Josune Orbe, Jose Antonio Paramo, Jean-Jacques Parienti, Nancy J Rothwell, Marina Rubio, Christian Waeber, Alan R Young, Emmanuel Touzé, Denis Vivien |
| Abstract |
The debate over the fact that experimental drugs proposed for the treatment of stroke fail in the translation to the clinical situation has attracted considerable attention in the literature. In this context, we present a retrospective pooled analysis of a large data set from preclinical studies, to examine the effects of early versus late administration of intravenous recombinant tissue-type plasminogen activator. We collected data from 26 individual studies from 9 international centers (13 researchers; 716 animals) that compared recombinant tissue-type plasminogen activator with controls, in a unique mouse model of thromboembolic stroke induced by an in situ injection of thrombin into the middle cerebral artery. Studies were classified into early (<3 hours) versus late (≥3 hours) drug administration. Final infarct volumes, assessed by histology or magnetic resonance imaging, were compared in each study, and the absolute differences were pooled in a random-effect meta-analysis. The influence of time of administration was tested. When compared with saline controls, early recombinant tissue-type plasminogen activator administration was associated with a significant benefit (absolute difference, -6.63 mm(3); 95% confidence interval, -9.08 to -4.17; I(2)=76%), whereas late recombinant tissue-type plasminogen activator treatment showed a deleterious effect (+5.06 mm(3); 95% confidence interval, +2.78 to +7.34; I(2)=42%; Pint<0.00001). Results remained unchanged after subgroup analyses. Our results provide the basis needed for the design of future preclinical studies on recanalization therapies using this model of thromboembolic stroke in mice. The power analysis reveals that a multicenter trial would require 123 animals per group instead of 40 for a single-center trial. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 40% |
| Spain | 1 | 20% |
| Georgia | 1 | 20% |
| Unknown | 1 | 20% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 2 | 40% |
| Practitioners (doctors, other healthcare professionals) | 2 | 40% |
| Members of the public | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 71 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | 1% |
| Unknown | 70 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 18% |
| Student > Bachelor | 9 | 13% |
| Student > Ph. D. Student | 7 | 10% |
| Student > Master | 5 | 7% |
| Student > Doctoral Student | 4 | 6% |
| Other | 14 | 20% |
| Unknown | 19 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 21% |
| Neuroscience | 14 | 20% |
| Biochemistry, Genetics and Molecular Biology | 7 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 7% |
| Agricultural and Biological Sciences | 3 | 4% |
| Other | 8 | 11% |
| Unknown | 19 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 June 2022.
All research outputs
#4,102,965
of 25,377,790 outputs
Outputs from Stroke
#3,979
of 12,372 outputs
Outputs of similar age
#61,022
of 315,348 outputs
Outputs of similar age from Stroke
#76
of 145 outputs
Altmetric has tracked 25,377,790 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,372 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 16.6. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 315,348 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 145 others from the same source and published within six weeks on either side of this one. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.